Evidence map›Paper›PMID 34436447›Full record

ArticleMetabolites2021

Comparison of Osteosarcoma Aggregated Tumour Models with Human Tissue by Multimodal Mass Spectrometry Imaging.

Lucy E Flint, Gregory Hamm, Joseph D Ready, Stephanie Ling, Catherine J Duckett, Neil A Cross, Laura M Cole, David P Smith, Richard J A Goodwin, Malcolm R Clench

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Lucy E FlintCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.
Gregory HammImaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, UK.
Joseph D ReadyCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.ORCID 0000-0002-1036-4970
Stephanie LingImaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, UK.
Catherine J DuckettCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.
Neil A CrossCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.
Laura M ColeCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.ORCID 0000-0002-2538-6291
David P SmithCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.ORCID 0000-0001-5177-8574
Richard J A GoodwinImaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, UK.
Malcolm R ClenchCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.
Sheffield Hallam University · GBAstraZeneca (United Kingdom) · GB

Funding

National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/L001896/1
6 · The paper itself

Abstract

Osteosarcoma (OS) is the most common primary bone malignancy and largely effects adolescents and young adults, with 60% of patients under the age of 25. There are multiple cell models of OS described in vitro that express the specific genetic alterations of the sarcoma. In the work reported here, multiple mass spectrometry imaging (MSI) modalities were employed to characterise two aggregated cellular models of OS models formed using the MG63 and SAOS-2 cell lines. Phenotyping of the metabolite activity within the two OS aggregoid models was achieved and a comparison of the metabolite data with OS human tissue samples revealed relevant fatty acid and phospholipid markers. Although, annotations of these species require MS/MS analysis for confident identification of the metabolites. From the putative assignments however, it was suggested that the MG63 aggregoids are an aggressive tumour model that exhibited metastatic-like potential. Alternatively, the SAOS-2 aggregoids are more mature osteoblast-like phenotype that expressed characteristics of cellular differentiation and bone development. It was determined the two OS aggregoid models shared similarities of metabolic behaviour with different regions of OS human tissues, specifically of the higher metastatic grade.

Indexed as

DESIimaging mass cytometryLA-ICP-MSmass spectrometry imagingmetabolomicsosteosarcoma

Identifiers

PMID34436447
PMCPMC8401535
OpenAlexW3190145463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.